AstraZeneca PLC is 154.7x more valuable than Zymeworks Inc. by market capitalization ($286.27 B vs $1.85 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ZYME | AZN |
|---|---|---|
| Market cap | $1.85 B | $286.27 B |
| US-listed rank | #2155 | #45 |
| Revenue (latest FY) | $105.97M | - |
| Net income (latest FY) | -$81.13M | - |
| Net margin | -76.6% | - |
| SEC filings | 324 | 1,004 |
AstraZeneca PLC is 154.7x more valuable than Zymeworks Inc. by market capitalization ($286.27 B vs $1.85 B).
Full pages: Zymeworks Inc. and AstraZeneca PLC, or browse the full rankings.